News GeneTether Therapeutics Inc.

Equities

GTTX

CA37187D1087

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2024-04-16 am EDT			5-day change	1st Jan Change
0.045 ^CAD	-.--%		-.--%	+12.50%

Mar. 30	5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	CI
Mar. 29	GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	Mar. 29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
GeneTether Therapeutics Inc. Announces Fiscal Year 2023 Financial Results and Reports on Corporate Highlights	Mar. 28	AQ
GeneTether Therapeutics Inc. Announces Third Quarter 2023 Financial Results	Nov. 28	AQ
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 27	CI
GeneTether Therapeutics Board Provides Shareholder Update	23-10-20	AQ
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023.	23-09-29	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
GeneTether Therapeutics Engages Gad Berdugo, Managing Partner of Explorium Capital LLC, as Advisor to Explore Strategic Alternatives for GeneTether Technology Platform	23-05-01	AQ
GeneTether Therapeutics Inc. Announces Fiscal Year 2022 Financial Results and Reports on Corporate Highlights	23-04-27	AQ
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
GeneTether Therapeutics Inc. Update - From the Desk of the CEO	23-03-30	AQ
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	23-03-29	CI
GeneTether Therapeutics Inc. Announces Commencement of Strategic Review Process	23-02-08	AQ
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
GeneTether Therapeutics Inc. Announces Third Quarter 2022 Financial Results and Reports on Corporate Highlights	22-11-25	AQ
GeneTether Therapeutics Inc. Update - From the Desk of the CEO	22-10-25	AQ
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2022.	22-09-29	CI
GeneTether Therapeutics Inc. Announces Second Quarter 2022 Financial Results and Reports on Corporate Highlights	22-08-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News GeneTether Therapeutics Inc.

Equities

GTTX

CA37187D1087

Summary

Filters